DSS (DSS) 10-Q 14 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 11, 2020
Document And Entity Information
Entity Registrant Name	DOCUMENT SECURITY SYSTEMS INC
Entity Central Index Key	0000771999
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,078,687
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 3,802,000	$ 1,096,000
Accounts receivable, net of $2,000 and $41,000 respectively allowance for doubtful accounts	3,582,000	4,212,000
Inventory	1,743,000	1,708,000
Prepaid expenses and other current assets	514,000	460,000
Total current assets	9,641,000	7,476,000
Property, plant and equipment, net	4,925,000	5,061,000
Investment	2,154,000	2,154,000
Marketable securities	570,000
Notes receivable	1,255,000	793,000
Other assets	54,000	50,000
Right-of-use assets	1,119,000	1,223,000
Goodwill	1,769,000	2,454,000
Other intangible assets, net	816,000	935,000
Total assets	22,303,000	20,146,000
Current liabilities:
Accounts payable	1,489,000	1,492,000
Accrued expenses and deferred revenue	706,000	936,000
Other current liabilities	390,000	390,000
Revolving line of credit	800,000	500,000
Current portion of lease liability	369,000	397,000
Current portion of long-term debt, net	403,000	441,000
Total current liabilities	4,157,000	4,156,000
Long-term debt, net	2,427,000	2,310,000
Long term lease liability	750,000	826,000
Other long-term liabilities	507,000	507,000
Deferred tax liability, net	44,000	44,000
Commitments and contingencies (Note 8)
Stockholders' equity
Common stock, $.02 par value; 200,000,000 shares authorized, 2,069,000 shares issued and outstanding (1,206,000 on December 31, 2019)	42,000	24,000
Additional paid-in capital	119,624,000	115,560,000
Non-controlling interest in subsidiary	(67,000)
Accumulated deficit	(105,181,000)	(103,281,000)
Total stockholders' equity	14,418,000	12,303,000
Total liabilities and stockholders' equity	$ 22,303,000	$ 20,146,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts, accounts receivable	$ 2,000	$ 41,000
Common stock, par value	$ .02	$ .02
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	2,069,000	1,206,000
Common stock, shares outstanding	2,069,000	1,206,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue	$ 5,001,000	$ 4,809,000
Costs and expenses:
Cost of revenue, exclusive of depreciation and amortization	3,271,000	3,160,000
Selling, general and administrative (including stock based compensation)	2,641,000	1,777,000
Depreciation and amortization	360,000	294,000
Impairment of goodwill	685,000
Total costs and expenses	6,957,000	5,231,000
Operating loss	(1,956,000)	(422,000)
Other income (expense):
Interest income	24,000	2,000
Interest expense	(39,000)	(30,000)
Gain on marketable securities	4,000
Amortization of deferred financing costs and debt discount		(1,000)
Loss before income taxes	(1,967,000)	(451,000)
Income tax expense (benefit)
Net loss	(1,967,000)	(451,000)
Add: loss attributed to non-controlling interest	67,000
Net loss to common stockholders	(1,900,000)	(451,000)
Other comprehensive loss:
Interest rate swap loss		(1,000)
Comprehensive loss:	$ (1,967,000)	$ (452,000)
Loss per common share:
Basic	$ (1.23)	$ (0.77)
Diluted	$ (1.23)	$ (0.77)
Shares used in computing loss per common share:
Basic	1,539,052	583,158
Diluted	1,539,052	583,158
Printed Products [Member]
Revenue:
Total revenue	$ 3,949,000	$ 4,366,000
Technology Sales, Services and Licensing [Member]
Revenue:
Total revenue	479,000	443,000
Direct marketing [Member]
Revenue:
Total revenue	$ 573,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,967,000)	$ (451,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	360,000	294,000
Stock based compensation	90,000	31,000
Unrealized gain on investment	(4,000)
Amortization of deferred financing costs and debt discount		1,000
Impairment of goodwill	685,000
Decrease (increase) in assets:
Accounts receivable	630,000	(278,000)
Inventory	(35,000)	218,000
Prepaid expenses and other current assets	(54,000)	1,000
Other assets	(4,000)
Increase (decrease) in liabilities:
Accounts payable	(3,000)	(101,000)
Accrued expenses	(167,000)	(213,000)
Other liabilities		(378,000)
Net cash used by operating activities	(469,000)	(876,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(105,000)	(211,000)
Purchase of marketable securities	(566,000)
Note receivable investment	(462,000)
Purchase of intangible assets		(350,000)
Net cash used by investing activities	(1,133,000)	(561,000)
Cash flows from financing activities:
Payments of long-term debt	(121,000)	(57,000)
Borrowings of long-term debt	200,000
Borrowings from revolving lines of credit, net	300,000
Borrowings from convertible of note		500,000
Issuances of common stock, net of issuance costs	3,929,000	(7,000)
Net cash provided by financing activities	4,308,000	436,000
Net increase (decrease) in cash	2,706,000	(1,001,000)
Cash at beginning of period	1,096,000	2,448,000
Cash at end of period	$ 3,802,000	$ 1,447,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Non - controlling Interest in Subsidiary [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 11,000	$ 107,962,000	$ (7,000)		$ (100,392,000)	$ 7,574,000
Balance, shares at Dec. 31, 2018	581,000
Issuance of common stock, net		$ 638,000				$ 638,000
Issuance of common stock, net, shares	19,000
Stock based payments, net of tax effect		$ 31,000				$ 31,000
Other comprehensive loss			(1,000)			(1,000)
Net loss					(451,000)	(451,000)
Balance at Mar. 31, 2019	$ 11,000	108,631,000	(8,000)		(100,843,000)	7,791,000
Balance, shares at Mar. 31, 2019	600,000
Balance at Dec. 31, 2019	$ 24,000	$ 115,560,000			$ (103,281,000)	$ 12,303,000
Balance, shares at Dec. 31, 2019	1,206,000
Issuance of common stock, net	$ 18,000	$ 4,036,000				$ 4,054,000
Issuance of common stock, net, shares	863,000
Stock based payments, net of tax effect		$ 28,000				$ 28,000
Net loss				(67,000)	(1,900,000)	(1,967,000)
Balance at Mar. 31, 2020	$ 42,000	$ 119,624,000		$ (67,000)	$ (105,181,000)	$ 14,418,000
Balance, shares at Mar. 31, 2020	2,069,000

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Document Security Systems, Inc. (the “Company”) operates nine (9) business lines through nine (9) DSS subsidiaries located around the globe. Of the nine subsidiaries, four of those have historically been the core subsidiaries of the Company: (1) Premier Packaging Corporation (DSS Packaging and Printing Group), (2) Plastic Printing Professionals, Inc (DSS Plastics Group), (3) DSS Digital Inc., and its subsidiaries (DSS Digital Group), and (4) DSS Technology Management, Inc. (DSS Technology Management). Premier Packaging Corporation operates in the paper board folding carton, smart packaging and document security printing markets, Plastic Printing Professionals, Inc. operates in the security printing and plastic ID systems market. These two companies develop, market, manufacture and sell paper and plastic products designed to protect valuable information from unauthorized scanning, copying, and digital imaging. DSS Digital Inc., researches, develops, markets and sells the Company’s digital products worldwide. The primary product is AuthentiGuard®, which is a brand authentication application that integrates the Company’s counterfeit deterrent technologies with proprietary digital data security-based solutions. DSS Technology Management Inc., manages, licenses and acquires intellectual property (“IP”) assets for the purpose of monetizing these assets through a variety of value-enhancing initiatives, including, but not limited to, investments in the development and commercialization of patented technologies, licensing, strategic partnerships and commercial litigation. In 2020, under its Decentralize Sharing Systems, Inc. subsidiary, created a fifth business segment, Direct Marketing. Direct marketing or network marketing is designed to sell products or services directly to the public through independent distributors, rather than selling through the traditional retail market. In addition to the four subsidiaries listed above, in 2019 and early 2020, DSS has created five new, wholly owned subsidiaries. (5) DSS Blockchain Security, Inc., a Nevada corporation, that intends to specialize in the development of blockchain security technologies for tracking and tracing solutions for supply chain logistics and cyber securities across global markets. (6) Decentralize Sharing Systems, Inc., a Nevada corporation, seeks to provide services to assist companies in the new business model of the peer-to-peer decentralized sharing marketplaces. (7) DSS Securities, Inc., a Nevada corporation, has been established to develop or to acquire assets in the securities trading or management arena, and to pursue two parallel streams of digital asset exchanges in multiple jurisdictions: (i) securitized token exchanges, focusing on digitized assets from different vertical industries and (ii) utilities token exchanges, focusing on “blue-chip” utility tokens from solid businesses. (8) DSS BioHealth Security, Inc., a Nevada corporation, is our business line which we will intend to invest in or to acquire companies related to the biohealth and biomedical field, including businesses focused on the research to advance drug discovery and development for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. This new division will place special focus on open-air defense initiatives, which curb transmission of air-borne infectious diseases such as tuberculosis and influenza, among others. (9) DSS Secure Living, Inc., a Nevada Corporation, intends to develop top of the line advanced technology, energy efficiency, quality of life living environments and home security for everyone for new construction and renovations of residential single and multifamily living facilities. Aside from Decentralized Sharing Systems, Inc. the activity in the these newly created subsidiaries have been minimal or in various start-up or organizational phases. On March 3, 2020, the Company, via its subsidiary DSS Securities, entered into a share subscription agreement and loan arrangement with LiquidValue Asset Management Pte Ltd., AMRE Asset Management, Inc. and American Medical REIT Inc. under which it acquired a 52.5% controlling ownership interest in AMRE Asset Management Inc. (“AAMI”) which currently has a 93% equity interest in American Medical REIT Inc. (“AMRE”) (see Note 4). AAMI is a real estate investment trust (“REIT”) management company that sets the strategic vision and formulate investment strategy for AMRE. It manages the REIT’s assets and liabilities and provides recommendations to AMRE on acquisition and divestments in accordance with the investment strategies. American Medical REIT, Inc is a Maryland corporation, organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. AMRE was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. AMRE is planned to qualify as a Real Estate Investment Trust for federal income tax purposes, which will provide. AMRE’s investors the opportunity for direct ownership of Class A licensed medical real estate. As of March 31, 2020 there have been no portfolio of licensed medical real estate originated or acquired. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8.03 of Regulation S-X for smaller reporting companies. Accordingly, these statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying balance sheets and related interim statements of operations and comprehensive loss and cash flows include all adjustments considered necessary for their fair presentation in accordance with U.S. GAAP. All significant intercompany transactions have been eliminated in consolidation. Interim results are not necessarily indicative of results expected for the full year. For further information regarding the Company’s accounting policies, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2019. Principles of Consolidation - Use of Estimates - Reclassifications Investment Marketable Securities Fair Value of Financial Instruments ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments carried at cost less impairment; however, the fair value is not considered readily determinable based on the lack of liquidity for the shares owned. Impairment of Long-Lived Assets and Goodwill Contingent Legal Expenses - Business Combinations - Earnings Per Common Share For the three months ended March 31, 2020 and 2019, common stock equivalents were excluded from the calculation of diluted earnings per share as the Company had a net loss, since their inclusion would have been anti-dilutive. Concentration of Credit Risk - During the three months ended March 31, 2020, two customers accounted for approximately 25% and 12%, respectively, of the Company’s consolidated revenue and accounted for 54% and 5%, respectively, of the Company’s accounts receivable balance as of March 31, 2020. The risk with respect to accounts receivables is mitigated by credit evaluations the Company performs on its customers, the short duration of its payment terms for most of its customer contracts and by the diversification of its customer base. Income Taxes Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment”, which eliminates the two-step process that required identification of potential impairment and a separate measure of the actual impairment. The annual assessment of goodwill impairment will be determined by using the difference between the carrying amount and the fair value of the reporting unit. The standards update is effective for goodwill impairment tests in fiscal years beginning after December 15, 2019 and has been adopted by the Company effective January 1, 2020. Impact of COVID-19 Outbreak - Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including losses on inventory; impairment losses related to goodwill and other long-lived assets and current obligations Continuing Operations and Going Concern – The expected use of cash for operations in 2020 will be primarily for funding, working capital, acquisition and investment opportunities, and the continued R&D costs, associated with the AuthentiGuard product line and the sales and marketing costs associated with the continued global roll-out of the product. The Company will also use these funds to make capital improvements at its two manufacturing facilities to increase production capacity and create efficiencies, as well as to diversify its revenue streams and take advantage of profit opportunities. The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters includes, among other things, continued growth among our operating segments including international expansion of our AuthentiGuard product, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn of its IP Monetization program. At the Company’s current operating levels and capital usage, we believe that our $3.8 million in aggregate cash and equivalents as of March 31, 2020 would allow us to fund our nine business lines current and planned operations through May 2021. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue	2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return. The Company also derives revenue from royalties from third parties which are typically based on licensees’ net sales of products that utilize the Company’s technology, or on a per item usage of the technology on the customers’ printed products. The Company recognizes license revenue at the time it is reported by the licensee. From time to time, the Company generates license revenues through litigation settlements. For these, the Company recognizes revenue upon the execution of the agreement, when collectability is reasonably assured, or upon receipt of the minimum upfront fee for term agreement renewals, and when all other revenue recognition criteria have been met. As of March 31, 2020, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Accounts Receivable The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 105 for certain customers. The Company carries its trade accounts receivable at invoice amount less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. At March 31, 2020, the Company established a reserve for doubtful accounts of approximately $2,000 ($41,000 – December 31, 2019). The Company does not accrue interest on past due accounts receivable. Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of March 31, 2020. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue. See Note 11 for disaggregated revenue information.

Notes Receivable

Notes Receivable	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Notes Receivable	3. Notes Receivable On October 10, 2019, the Company entered into a convertible promissory note (“TBD Note”) with Century TBD Holdings, LLC (“TBD”), a Florida limited liability company. The Company loaned the principal sum of $500,000, of which up to $500,000 and all accrued interest can be paid by an “Optional Conversion” of such amount up to 19.8% (non-dilutable) of all outstanding membership interest in TBD. This TBD Note accrues interest at 6% and matures on October 9, 2021. As of March 31, 2020 and December 31, 2019 this TBD Note had outstanding principal and interest of approximately $514,000 and $507,000, respectively. On October 9, 2019 and November 11, 2019 the Company’s subsidiary Decentralized Sharing Systems, Inc. entered into two, separate on demand, secured, convertible notes with RBC Life Sciences, Inc. (RBC), a Nevada corporation. The first Note, dated October 9th, lent the principal sum of $200,000 and accrues interest at 6% with a maturity date of November 11, 2019 (“Note #1) This note also contains an “Optional Conversion” clause that allows the Company at any time, before or after the occurrence of an Event of Default, at its option, to convert the outstanding principal amount, plus accrued interest into a number of newly issued shares of its common stock equal to 75% of the total shares common stock that will be outstanding upon such conversion at a fully-diluted basis. Note #1 was also secured by and among other things all of the assets of RBC and its subsidiaries, and was guaranteed by its subsidiary, RBC Life Sciences USA, Inc. The Company had advanced $200,000 in principal Note #1 as of March 31, 2020 and December 31, 2019. The second Note (Note #2) dated November 11, 2019, established a secured, convertible, revolving line of credit to RBC up to an aggregate principal sum of $800,000, funded at the sole discretion of lender, and accruing at annual interest rate of 10% with a scheduled maturity date of November 11, 2024. Accrued interest on any outstanding principal balance was scheduled to be payable monthly commencing on December 25, 2019. Further, any amount of principal repaid during the term of the note is allowed to be re-advanced at any time prior to the earlier of the termination of this note or the maturity date. This note also contains an “Optional Conversion” clause that allows the Company at any time, before or after the occurrence of an Event of Default, at its option, to convert the outstanding principal amount, plus accrued interest into a number of newly issued shares of its common stock equal to 100% of the outstanding shares of common stock of RBC direct and indirect subsidiaries. This Note #2 was also secured by a 2nd lien on all of the assets of RBC, behind the first lien securing Note #1, and a first lien on all of the assets of RBC’s multiple subsidiaries and the full guarantee of these subsidiaries. The outstanding principal and interest balance of Note #2 as of March 31, 2020 and December 31, 2019, was approximately $533,000 and $83,000 respectively. On January 24, 2020, the Company exercised its rights under the terms of the promissory note, security agreements and the guarantee agreements, and declared Note #1 in default and sought to exercise its Uniform Commercial Code Article 9 rights to accept collateral in partial satisfaction of debt. The Company chose to not exercise its option convert the outstanding principal and interest into equity, but instead elected to accept specific collateral. On February 7, 2020, RBC agreed to the deed-in-lieu of specific assets in satisfaction of part of the amount owing under Note #1. A pending valuation of the accepted assets acquired through this deed-in-lieu is in process. On April 8, 2020, the Company initiated Uniform Commercial Code Article 9 foreclosure proceedings against the remaining assets of RBC and its subsidiaries at a public sale on April 23, 2020. Again, the Company chose to forego the optional conversion of the outstanding principal and interest into 100% ownership, as was allowed in the terms of the note. Instead it elected to pursue through a public foreclosure sale collateral that secured Note #2. As a result of the public the Company being the high bidder at that foreclosure sale, the Company now owns and controls certain former assets of RBC and its subsidiaries. A valuation of the assets acquired through foreclosure is pending.

Business Combination

Business Combination	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business Combination	4. Business Combination On March 3, 2020, the Company entered into a binding term sheet (the “Term Sheet”) with LiquidValue Asset Management Pte Ltd (“LVAM”), AMRE Asset Management Inc. (“AAMI”) and American Medical REIT Inc. (“AMRE”), regarding a share subscription and loan arrangement. The Term Sheet set forth the terms of a proposed transaction to establish a medical real estate investment trust in the United States and AAMI providing certain services related to the financial and capital structure of AMRE. Pursuant to the Term Sheet, the Company has subscribed 5,250 ordinary shares of AAMI at a purchase price of $0.01 per share for total consideration of $52.50. Concurrently, AAMI will issue 2,500 shares to LVAM, and 1,250 shares to AMRE Tennessee, LLC, AAMI’s executive management’s holding company (collectively, the “Subscription Shares”). As a result, the Company now holds 52.5% of the outstanding shares of AAMI, with LVAM and AMRE Tennessee, LLC, holding 35% and 12.5% of the remaining outstanding shares of AAMI, respectively. At the completion of the share subscription, AAMI has a 93% equity interest in AMRE. Also at the completion of the transaction, AAMI had no assets or liabilities. LVAM is an 82% owned subsidiary of Singapore eDevelopment Limited whose Chief Executive Office and largest shareholder is Heng Fai Ambrose Chan, the Chairman of the Board and largest shareholder of the Company. Further, pursuant to and in connection with the Term Sheet, effective on March 3, 2020, the Company entered into a Promissory Note with AMRE, pursuant to which AMRE has issued the Company a promissory note for the principal amount of $800,000.00 (the “Note”). The Note matures on March 3, 2022 and accrues interest at the rate of 8.0% per annum and shall be payable in accordance with the terms set forth in the Note. Under the Note, AMRE may prepay or repay all or any portion of the Note at any time, without a premium or penalty. If not sooner prepaid, the entire unpaid principal balance of the Note including accrued interest will be due and payable in full on March 3, 2022. AMRE’s failure to pay any amount due on the Note within five days of when payment is due constitutes an event of default under the Note, pursuant to which the Company can declare the Note due and payable. The Note also provides the Company an option to provide AMRE an additional $800,000 on the same terms and conditions as the Note, including the issuance of warrants as described below. As further incentive to enter into the Note, AMRE issued the Company warrants to purchase 160,000 shares of AMRE common stock (the “Warrants”). The Warrants have an exercise price of $5.00 per share, subject to adjustment as set forth in the Warrants, and expire on March 3, 2024. Pursuant to the Warrants, if AMRE files a registration statement with the Securities and Exchange Commission for an initial public offering (“IPO”) of AMRE’s common stock and the IPO price per share offered to the public is less than $10.00 per share, the exercise price of the Warrants shall be adjusted downward to 50% of the IPO price. The Warrants also grants piggyback registration rights to the Company as set forth in the Warrants. As of March 31, 2020, this Note had outstanding principal and interest of approximately $802,000. Upon consolidation this Note is eliminated. U.S. GAAP requires that for each business combination, one of the combining entities shall be identified as the acquirer, and the existence of a controlling financial interest shall be used to identify the acquirer in a business combination. The Company has determined that its aforementioned 52.5% equity interest in AAMI provides existence of a controlling financial interest and has concluded to account for this transaction in accordance with the acquisition method of accounting under FASB ASC Topic 805, “ Business Combinations”

Investment

Investment	3 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Investment	5. Investment The Company owns 83,174,129 ordinary shares of Singapore eDevelopment Limited (“SED”) a company incorporated in Singapore and publicly listed on the Singapore Exchange Limited, and an existing three-year warrant to purchase up to 44,005,182 ordinary shares at an exercise price of SGD$0.040 (US$0.0298) per share. The Company adopted ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities.” and carries its investment in SED at costs. The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of SED. The carrying value of the investment as of March 31, 2019 was approximately $2,154,000.

Short Term and Long-Term Debt

Short Term and Long-Term Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Short Term and Long-Term Debt	6. Short-Term and Long-Term Debt Revolving Credit Lines On July 26, 2017, Premier Packaging entered into a Loan Agreement and accompanying Term Note Non-Revolving Line of Credit Agreement with Citizens pursuant to which Citizens agreed to lend up to $1,200,000 to permit Premier Packaging to purchase equipment from time to time that it may need for use in its business. The aggregate principal balance outstanding under the Equipment Acquisition Line of Credit shall bear interest thereon at a per annum rate of 2% above the LIBOR Advantage Rate until the Conversion Date (as defined in the Term Note Non-Revolving Line of Credit). Effective on the Conversion Date, the interest shall be adjusted to a fixed rate equal to 2% above the bank’s Cost of Funds, as determined by Citizens. Current maturities of long-term debt are based on an estimated 48-month amortization which will be adjusted upon conversion. As of March 31, 2020, had a balance of $870,000. The Company pays a monthly amount of $13,000 in principal and interest. On December 1, 2017, the Company’s subsidiary Plastic Printing Professionals entered into a Loan Agreement and accompanying Term Note Non-Revolving Line of Credit Agreement with Citizens which was converted into two term notes under which the Company will make monthly payments of $14,000 until November 30, 2023. Interest under the term notes is payable monthly at 5.37%. As of March 31, 2020, the combined balance of the term notes was $544,000. Term Loan Debt Promissory Notes - The Citizens credit facilities to each of the Company’s subsidiaries, Premier Packaging and Plastic Printing Professionals, contain various covenants including fixed charge coverage ratio, tangible net worth and current ratio covenants which are tested annually at December 31. For the year ended December 31, 2019, Premier Packaging was in compliance with the annual covenants, however Plastic Printing Professionals was not. Plastic Printing Professionals has sought and received a one-time waiver from compliance from Citizens for this violation during the quarter ended March 31, 2020. On October 24, 2018, the Company’s subsidiary, DSS Asia Limited entered into a $100,000 unsecured promissory note with HotApps International Pte Ltd in conjunction with the acquisition of Guangzhou HotApps Technology Ltd., a Chinese subsidiary of HotApps International Pte Ltd, by DSS Asia Limited. The promissory note does not accrue interest and is payable in full on October 24, 2020. On March 2, 2020, AMRE entered into a $200,000 unsecured promissory note with LVAM. The Note calls for interest to be paid annually on March 2 with interest fixed at 8.0%. If not paid sooner, the entire unpaid principal balance is due in full on March 2, 2022. As further incentive to enter into this Note, AMRE granted LVAM warrants to purchase shares of common stock of AMRE (the “Warrants”). The amount of warrants granted is the equivalent of the Note Principal divided by the Exercise Price. The Warrants are exercisable for four years, and are exercisable at $5.00 per share (the “Exercise” Price). The value of the warrants is not considered to be material. The holder is a related party owned by the Chairman of the Company’s board of directors.

Lease Liability

Lease Liability	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lease Liability	7 . The Company has operating leases predominantly for operating facilities. As of March 31, 2020, the remaining lease terms on our operating leases range from less than one year to approximately four years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as of March 31, 2020. Future minimum lease payments as of March 31, 2020 are as follows: Totals 2020 295,000 2021 305,000 2022 290,000 2023 270,000 2024 22,000 Total lease payments 1,182,000 Less imputed interest (63,000 ) Lease liability 1,119,000 Current 369,000 Non-current 750,000 Weighted average remaining lease term (years) 3.41 Weighted average discount rate 5.37 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies On November 26, 2013, DSSTM filed suit against Apple, Inc. (“Apple”) in the United States District Court for the Eastern District of Texas, for patent infringement (the “Apple Litigation”). The complaint alleges infringement by Apple of DSSTM’s patents that relate to systems and methods of using low power wireless peripheral devices. DSSTM is seeking a judgment for infringement, injunctive relief, and compensatory damages from Apple. On October 28, 2014, the case was stayed by the District Court pending a determination of Apple’s motion to transfer the case to the Northern District of California. On November 7, 2014, Apple’s motion to transfer the case to the Northern District of California was granted. On December 30, 2014, Apple filed two Inter Partes Review (“IPR”) petitions with the Patent Trial and Appeal Board (“PTAB”) for review of the patents at issue in the case. The PTAB instituted the IPRs on June 25, 2015. The California District Court then stayed the case pending the outcome of those IPR proceedings. Oral arguments of the IPRs took place on March 15, 2016, and on June 17, 2016, PTAB ruled in favor of Apple on both IPR petitions. DSSTM then filed an appeal with the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) seeking reversal of the PTAB decisions. Oral arguments for the appeal were held on August 9, 2017. On March 23, 2018, the Federal Circuit reversed the PTAB, finding that the PTAB erred when it found the claims of U.S. Patent No. 6,128,290 to be unpatentable. The Federal Circuit affirmed its decision on July 12, 2018, when it denied Apple’s petition for panel rehearing of the Federal Circuit’s Opinion and Judgment issued on March 23, 2018. On July 27, 2018, the District Court judge lifted the Stay resuming the litigation, which had a trial date set for the week of February 24, 2020. On January 14, 2020, the Court in the case DSS Technology Management, Inc. v. Apple, Inc. DSS Technology Management v. Apple On April 13, 2017, the Company filed a patent infringement lawsuit against Seoul Semiconductor Co., Ltd. and Seoul Semiconductor, Inc. (collectively, “Seoul Semiconductor”) in the United States District Court for the Eastern District of Texas, alleging infringement of certain of the Company’s Light-Emitting Diode (“LED”) patents. The Company is seeking a judgment for infringement of the patents along with other relief including, but not limited to, money damages, costs and disbursements. On June 7, 2017, the Company refiled its patent infringement complaint against Seoul Semiconductor in the United States District Court for the Central District of California, Southern Division. On December 3, 2017, Seoul Semiconductor filed an IPR challenging the validity of certain claims of U.S. Patent No. 6,949,771. This IPR was instituted by the PTAB on June 7, 2018. On April 18, 2019, the PTAB issued a written decision determining claims 1-9 of the ‘771 patent unpatentable. The Company did not appeal that determination. On December 21, 2017, Seoul Semiconductor filed an IPR challenging the validity of certain claims of U.S. Patent No. 7,256,486. This IPR was instituted by the PTAB on June 21, 2018. On June 10, 2019, the PTAB issued a written decision determining claims 1-3 of the ‘486 patent unpatentable. On August 12, 2019, the Company filed a Notice of Appeal with the Federal Circuit Court of Appeals challenging the PTAB’s decisions. The Company subsequently filed a motion to vacate and remand the PTAB’s decision in light of intervening precedent under the Appointments Clause. That motion was granted on January 23, 2020. On January 25, 2018, Seoul Semiconductor filed an IPR challenging the validity of certain claims of U.S. Patent No. 7,524,087. This IPR was instituted by the PTAB on July 27, 2018. On July 22, 2019, the PTAB issued a written decision determining claims 1, 6-8, 15, and 17 of the ‘087 patent unpatentable. On September 23, 2019, the Company filed a Notice of Appeal with the Federal Circuit Court of Appeals challenging the PTAB’s decisions. The Company subsequently filed a motion to vacate and remand the PTAB’s decision in light of intervening precedent under the Appointments Clause. That motion was granted on February 3, 2020. These challenged patents are the patents that are the subject matter of the infringement lawsuit, which is pending but stayed pending the outcome of the IPR proceedings. On April 13, 2017, the Company filed a patent infringement lawsuit against Cree, Inc. (“Cree”) in the United States District Court for the Eastern District of Texas, alleging infringement of certain of the Company’s LED patents. The Company is seeking a judgment for infringement of the patents along with other relief including, but not limited to, money damages, costs and disbursements. On June 8, 2017, the Company refiled its patent infringement complaint against Cree in the United States District Court for the Central District of California, and thereafter filed a first amended complaint for patent infringement against Cree in that same court on July 14, 2017. The case is currently pending as of the date of this Report. On June 6, 2018, Cree filed an IPR petition challenging the validity of claims under U.S. Patent No. 7,256,486. This IPR was instituted and joined with the Seoul Semiconductor IPR. On June 7, 2018, Cree filed IPR petitions challenging the validity of certain claims U.S. Patent Nos. 7,524,087 and 6,949,771. Both IPRs were denied by the PTAB on November 14, 2018 as time barred. The challenged patent is the patent that is the subject matter of the infringement lawsuit, which is pending but stayed pending the outcome of the IPR. On August 15, 2017, the Company filed a patent infringement lawsuit against Lite-On, Inc., and Lite-On Technology Corporation (collectively, “Lite-On”) in the United States District Court for the Central District of California, alleging infringement of certain of the Company’s LED patents. The Company is seeking a judgment for infringement of the patents along with other relief including, but not limited to, money damages, costs and disbursements. The case is currently pending but is stayed pending the outcome of IPR proceedings filed by other parties. On December 7, 2017, DSS filed a patent infringement lawsuit against Nichia Corporation and Nichia America Corporation in the United States District Court for the Central District of California, alleging infringement of certain of DSS’s LED patents. The Company is seeking a judgment for infringement of the patents along with other relief including, but not limited to, money damages, costs and disbursements. The case is currently pending as of the date of this Report. On May 10, 2018, Nichia filed an IPR petition challenging the validity of claims under U.S. Patent No. 7,919,787. On May 11, 2018, Nichia filed an IPR petition challenging the validity of claims under U.S. Patent No. 7,652,297. On May 25, 2018, Nichia filed an IPR petition challenging the validity of claims under U.S. Patent No. 7,524,087. On May 29, 2018, Nichia filed an IPR petition challenging the validity of claims under U.S. Patent No. 6,949,771. On May 30, 2018, Nichia filed an IPR petition challenging the validity of claims under U.S. Patent No. 7,256,486. The 6,949,771 IPR was denied institution, but the remaining IPRs were instituted by the PTAB. On December 10, 2018, Nichia refiled IPRs relating to 6,949,771, which was denied by the PTAB on April 15, 2019. These challenged patents are the patents that are the subject matter of the infringement lawsuit, which is pending but stayed pending the outcome of the IPR proceedings. On September 17, 2019, the PTAB issued a written decision determining claims 1-14 of the ‘787 patent unpatentable. The Company did not appeal that determination. On October 30, 2019, the PTAB issued a written decision determining claims 1-17 of the ‘297 patent unpatentable. The Company did not appeal that determination. On November 19, 2019, the PTAB issued a written decision determining claims 1-5 of the ‘486 patent unpatentable. The Company has appealed that determination to the U.S. Court of Appeals for the Federal Circuit. In April 2019 DSS commenced an action in New York State Supreme Court, Monroe County against Jeffrey Ronaldi, our former Chief Executive Officer. This New York action seeks a declaratory judgment that, contrary to informal claims made by him, Mr. Ronaldi’s employment agreement with us expired by its terms and that he is not entitled to any cash bonuses or other unpaid amounts. The lawsuit also seeks an injunction against Mr. Ronaldi from interfering with any of DSS’ IP litigation. The defendant has been granted an extension to respond pending settlement negotiations. Mr. Ronaldi subsequently commenced an action against us in the Superior Court of California, County of San Diego, in November 2019, in which he alleges that we terminated his employment in April 2019 in order to avoid paying him certain employment-related amounts. Mr. Ronaldi contends that he is owed a $100,000 performance bonus for 2017 under this employment agreement with us as well as $91,000 in documented and unreimbursed expenses, and that DSS purported to terminate him for cause under the terms of his employment agreement in order to avoid paying such amounts. Mr. Ronaldi also contends that he is entitled to receive additional amounts, either under the terms of the employment agreement, or under theories of implied-in-fact contract or promissory estoppel, including, but not limited to, (i) additional performance bonuses of up to 15% of net litigation proceeds received by us from pending patent infringement litigations, of net licensing proceeds received by us other than from our internally developed IP, or of the net sales proceeds received by us in connection with the sale of any of our patent assets, (ii) earned but unpaid base salary, (iii) an equity grant of shares of our common stock, and (iv) payments for unused personal time and sick days. He seeks actual, compensatory, restitutionary and/or incidental damages in an amount to be determined at trial; prejudgment interest in an amount to be determined at trial; attorneys’ fees and costs; other costs of the suit; and such other and further relief as the court deems proper. We have made a motion to have the case dismissed and consolidated with the Monroe Co., New York, litigation. A hearing was set for April 24, 2020, for the court to consider that request, but due to the closure of the court due to pandemic a new date for the hearing will be set as soon as the court is back in operation. Additionally, on March 2, 2020 DSS and DSSTM filed a second litigation action against Jeffrey Ronaldi in the State of New York, Supreme Court, County of Monroe, Document Security Systems, Inc. and DSS Technology Management, Inc. vs. Jeffrey Ronaldi On September 18, 2019, DSS filed a patent infringement lawsuit against Seoul Semiconductor Co., Ltd. and Seoul Semiconductor Inc. in the United States District Court for the Central District of California alleging infringement of U.S. Patent No. 7,315,119. The Company is seeking a judgment for infringement of the patents along with other relief including, but not limited to, money damages, costs and disbursements. The Court has conducted an initial scheduling conference and has set a procedural schedule for the case. On September 19, 2019, DSS filed a patent infringement lawsuit against Cree, Inc. in the United States District Court for the Central District of California alleging infringement of U.S. Patent No. 6,784,460. The Company is seeking a judgment for infringement of the patents along with other relief including, but not limited to, money damages, costs and disbursements. On February 11, 2020, Dree filed an IPR petition challenging the validity of the patent claims. The Court has conducted an initial scheduling conference and has set a procedural schedule for the case. On September 20, 2019, DSS filed a patent infringement lawsuit against Nichia Corp. and Nichia America Corp. in the United States District Court for the Central District of California alleging infringement of U.S. Patent No. 6,879,040. The Company is seeking a judgment for infringement of the patents along with other relief including, but not limited to, money damages, costs and disbursements. The Court has conducted an initial scheduling conference and has set a procedural schedule for the case. On November 20, 2019, DSS Technology Management was sued in the United States District Court, Northern District of California, by Intel Corporation (“Intel”) and Apple Inc. (“Apple”). The other defendants in the litigation are Fortress Investment Group LLC, Fortress Credit Co. LLC, Uniloc 2017 LLC, Uniloc USA, INC., Uniloc Luxembourg S.A.R.L., VLSI Technology LLC, INVT SPE LLC, Inventergy Global, INC., IXI IP, LLC, and Seven Networks, LLC. The complaint includes allegations regarding a February 13, 2014 Investment Agreement between DSS Technology Management and Fortress Credit Co. LLC as well as two subsequent agreements. The complaint also contains allegations regarding DSS Technology Management’s lawsuit against Intel that was filed in February 2015 in the United States District Court, Eastern District of Texas (referred to below). In the complaint, Intel and Apple allege violations of Section 1 of the Sherman Act and unfair competition under Cal. Bus. & Prof. Code § 17200 against DSS Technology Management. Additional claims are alleged against other defendants. Intel and Apple seek relief from the court including that defendants’ conduct be declared a violation of Section 1 of the Sherman Act, Section 7 of the Clayton Act, and Cal. Bus. & Prof. Code § 17200, et seq.; that Intel and Apple recover damages against defendants in an amount to be determined and multiplied to the extent provided by law, including under Section 4 of the Clayton Act; that all contracts or agreements defendants entered into in violation of the Sherman Act, Clayton Act, or Cal. Bus. & Prof. Code § 17200, et seq. be declared void and the patents covered by those transfer agreements be transferred back to the transferors; that all patents transferred to defendants in violation of the Sherman Act, Clayton Act, or Cal. Bus. & Prof. Code § 17200, et seq. be declared unenforceable; and that Intel and Apple recover their costs and expenses associated with this case, together with interest. DSS Technology Management responded to the complaint on February 4, 2020 by filing a motion to dismiss and strike the complaint as well as a motion to stay discovery. The court granted the motion to stay discovery on March 25, 2020. A hearing on the motion to dismiss and to strike the complaint is set for June 18, 2020. In addition to the foregoing, we may become subject to other legal proceedings that arise in the ordinary course of business and have not been finally adjudicated. Adverse decisions in any of the foregoing may have a material adverse effect on our results of operations, cash flows or our financial condition. The Company accrues for potential litigation losses when a loss is probable and estimable. Contingent Litigation Payments Contingent Payments

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Sales of Equity – On February 18, 2020, in accordance with the Chairman of the Company’s Board of Directors compensation plan as CEO of one of the Company’s subsidiaries,11,664 shares of the Company’s common stock were remitted in lieu of cash as settlement of his Q3 and Q4 2019 salary of $114,000 that was accrued as of December 31, 2019. Additionally, the Company has accrued approximately $61,000 representing his salary for Q1 2020 that has not yet been settled. This amount was recorded as stock-based compensation for the three months ended March 31, 2020. Stock-Based Compensation -

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	10. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the three-month periods ended March 31, 2020 and 2019: 2020 2019 Cash paid for interest $ 39,000 $ 30,000 Non-cash investing and financing activities: Impact of adoption of lease accounting standards $ - $ 1,498,000 Loss from change in fair value of interest rate swap derivatives $ - $ (1,000 ) Common stock issued upon conversion of convertible note $ - $ 500,000 Equity issued to purchase intangible assets $ - $ 145,000 Satisfaction of accrued expenses with issuance of common stock $ 114,000 $ -

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Information	11. Segment Information The Company’s nine businesses lines e.g Approximate information concerning the Company’s operations by reportable segment for the three-month ended March 31, 2020 and 2019 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Period Ended March 31, 2020 Packaging and Printing Plastics Digital Technology Management Direct Marketing Corporate Total Revenue $ 3,158,000 $ 780,000 $ 490,000 $ - $ 573,000 $ - $ 5,001,000 Depreciation and amortization 223,000 57,000 9,000 14,000 - 57,000 360,000 Interest expense 27,000 8,000 4,000 - - - 39,000 Stock based compensation 4,000 - 20,000 - - 66,000 90,000 Impairment of goodwill - (685,000 ) - - - - (685,000 ) Net Income (loss) 22,000 (1,046,000 ) (46,000 ) (241,000 ) 204,000 (860,000 ) (1,967,000 ) Capital expenditures 63,000 37,000 4,000 - - 1,000 105,000 Identifiable assets $ 10,626,000 $ 2,962,000 $ 757,000 $ - $ 865,000 $ 7,093,000 $ 22,303,000 Period Ended March 31, 2019 Packaging and Printing Plastics Digital Technology Management Direct Marketing Corporate Total Revenue $ 3,313,000 $ 1,053,000 $ 443,000 $ - $ - $ - $ 4,809,000 Depreciation and amortization 225,000 41,000 28,000 - - - 294,000 Interest expense 22,000 6,000 2,000 - - - 30,000 Stock based compensation 4,000 - 23,000 - - 4,000 31,000 Impairment of goodwill - - - - - - - Net Income (loss) 89,000 (17,000 ) (321,000 ) (56,000 ) - (146,000 ) (451,000 ) Capital expenditures 126,000 77,000 8,000 - - - 211,000 Identifiable assets $ 9,248,000 $ 4,506,000 $ 1,124,000 $ 110,000 $ - $ 1,182,000 $ 16,170,000 The following tables disaggregate our business segment revenues by major source. Printed Products Revenue Information: Three months ended March 31, 2020 Packaging Printing and Fabrication $ 2,966,000 Commercial and Security Printing 203,000 Technology Integrated Plastic Cards and Badges 220,000 Plastic Cards, Badges and Accessories 560,000 Total Printed Products $ 3,949,000 Three months ended March 31, 2019 Packaging Printing and Fabrication $ 2,961,000 Commercial and Security Printing 352,000 Technology Integrated Plastic Cards and Badges 503,000 Plastic Cards, Badges and Accessories 550,000 Total Printed Products $ 4,366,000 Technology Sales, Services and Licensing Revenue Information: Three months ended March 31, 2020 Information Technology Sales and Services $ 11,000 Digital Authentication Products and Services 331,000 Royalties from Licensees 137,000 Total Printed Products $ 479,000 Three months ended March 31, 2019 Information Technology Sales and Services $ 74,000 Digital Authentication Products and Services 230,000 Royalties from Licensees 139,000 Total Printed Products $ 443,000 Direct Marketing Three months ended March 31, 2020 Direct Marketing Internet Sales $ 573,000 Total Direct Marketing $ 573,000 Three months ended March 31, 2019 Direct Marketing Internet Sales $ - Total Direct Marketing $ -

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	12. SUBSEQUENT EVENTS On May 4, 2020, Document Security Systems, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) at which the Company’s stockholders approved amendment to the Company’s certificate of incorporation to effect a reverse split of common stock of the Company by a ratio of 1-for-30 (the “Reverse Split”) with the effectiveness of such amendment to be determined by the Board of Directors of the Company (the “Board”). The form of the certificate of amendment to effect the Reverse Split was subsequently approved by the Board on May 4, 2020. On May 7, 2020, the Company filed a Certificate of Amendment of Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of New York to effect a 1-for-30 reverse stock split of the Company’s outstanding common stock. The Amendment was effective at 5:01 p.m. Eastern Time on May 7, 2020 (the “Effective Time”). The reverse stock split has been retroactively applied to all financial statements presented. In April 2020, the Company received loan proceeds in the amount of approximately $963,000 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. On April 3, 2020, by unanimous written consent, the Board of Directors authorized the Company to issue individual stock grants of the Company’s common stock, pursuant to the Company’s 2020 Employee, Director and Consultant Equity Incentive Plan, to certain managers and directors in the amount of 8,900 shares, at $0.22 per share which were immediately vested and issued. 5,800 of these shares where were fully vested restricted stock to members of the Company’s management team of with a two-year lock-up period. On April 27, 2020, the Board of Directors of the Company approved and the Company entered into a share exchange agreement (the “Share Exchange Agreement”) with DSS BioHealth Security, Inc., a wholly owned subsidiary of the Company (“DBHS”), Singapore eDevelopment Limited, a Singapore corporation (“SeD”) that is listed on the Singapore Exchange, and Global BioMedical Pte Ltd, a Singapore corporation and wholly owned subsidiary of SeD (“GBM”), pursuant to which, among other things and subject to the terms and conditions contained therein, the DBHS will acquire of all of the outstanding capital stock (the “Impact Shares”) of Impact BioMedical Inc., a Nevada corporation and wholly owned subsidiary of GBM (“Impact BioMedical”) through a share exchange, with Impact BioMedical becoming a direct wholly owned subsidiary of the DBHS. The aggregate consideration for the Impact Shares will be the following to be issued to GBM by DSS (consideration prior to the reverse stock split noted above): (i) 14,500,000 newly issued shares of common stock of DSS, nominally valued at $3,132,000, or $0.216 per share; and (ii) 46,868 newly issued shares of a new series of perpetual convertible preferred stock of DSS (“Convertible Preferred Stock”) with a stated value of $46,868,000, or $1,000 per share, for a total consideration valued at $50 million. The Convertible Preferred Stock will be convertible into shares of common stock of DSS, subject to a 19.9% beneficial ownership conversion limitation (“blocker”) based on the total issued outstanding shares of common stock of DSS beneficially owned by GBM. Holders of the Convertible Preferred Stock will have no voting rights, except as required by applicable law or regulation, and no dividends will accrue or be payable on the Convertible Preferred Stock. The Holders of Convertible Preferred Stock will be entitled to a liquidation preference at a liquidation value of $1,000 per share, and the Company will have the right to redeem all or any portion of the then outstanding shares of Convertible Preferred Stock, pro rata among all holders, at a redemption price per share equal to such liquidation value per share. The closing of the purchase and sale of the Impact Shares contemplated under the Share Exchange Agreement is subject to a number of customary and other conditions, including both the Company and SeD having obtained approvals from their respective shareholders, SeD having obtained requisite approval from the Singapore Exchange, and receipt by DSS of audited financial statements of Impact BioMedical, which will be included in DSS’s proxy statement soliciting the vote of its shareholders.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation -
Use of Estimates	Use of Estimates -
Reclassifications	Reclassifications
Investment	Investment
Marketable Securities	Marketable Securities
Fair Value of Financial Instruments	Fair Value of Financial Instruments ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments carried at cost less impairment; however, the fair value is not considered readily determinable based on the lack of liquidity for the shares owned.
Impairment of Long-Lived Assets and Goodwill	Impairment of Long-Lived Assets and Goodwill
Contingent Legal Expenses	Contingent Legal Expenses -
Business Combinations	Business Combinations -
Earnings Per Common Share	Earnings Per Common Share For the three months ended March 31, 2020 and 2019, common stock equivalents were excluded from the calculation of diluted earnings per share as the Company had a net loss, since their inclusion would have been anti-dilutive.
Concentration of Credit Risk	Concentration of Credit Risk - During the three months ended March 31, 2020, two customers accounted for approximately 25% and 12%, respectively, of the Company’s consolidated revenue and accounted for 54% and 5%, respectively, of the Company’s accounts receivable balance as of March 31, 2020. The risk with respect to accounts receivables is mitigated by credit evaluations the Company performs on its customers, the short duration of its payment terms for most of its customer contracts and by the diversification of its customer base.
Income Taxes	Income Taxes
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment”, which eliminates the two-step process that required identification of potential impairment and a separate measure of the actual impairment. The annual assessment of goodwill impairment will be determined by using the difference between the carrying amount and the fair value of the reporting unit. The standards update is effective for goodwill impairment tests in fiscal years beginning after December 15, 2019 and has been adopted by the Company effective January 1, 2020.
Impact of COVID-19 Outbreak	Impact of COVID-19 Outbreak - Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including losses on inventory; impairment losses related to goodwill and other long-lived assets and current obligations
Continuing Operations and Going Concern	Continuing Operations and Going Concern – The expected use of cash for operations in 2020 will be primarily for funding, working capital, acquisition and investment opportunities, and the continued R&D costs, associated with the AuthentiGuard product line and the sales and marketing costs associated with the continued global roll-out of the product. The Company will also use these funds to make capital improvements at its two manufacturing facilities to increase production capacity and create efficiencies, as well as to diversify its revenue streams and take advantage of profit opportunities. The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters includes, among other things, continued growth among our operating segments including international expansion of our AuthentiGuard product, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn of its IP Monetization program. At the Company’s current operating levels and capital usage, we believe that our $3.8 million in aggregate cash and equivalents as of March 31, 2020 would allow us to fund our nine business lines current and planned operations through May 2021. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.

Lease Liability (Tables)

Lease Liability (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Future Minimum Lease payments	Future minimum lease payments as of March 31, 2020 are as follows: Totals 2020 295,000 2021 305,000 2022 290,000 2023 270,000 2024 22,000 Total lease payments 1,182,000 Less imputed interest (63,000 ) Lease liability 1,119,000 Current 369,000 Non-current 750,000 Weighted average remaining lease term (years) 3.41 Weighted average discount rate 5.37 %

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	The following table summarizes supplemental cash flows for the three-month periods ended March 31, 2020 and 2019: 2020 2019 Cash paid for interest $ 39,000 $ 30,000 Non-cash investing and financing activities: Impact of adoption of lease accounting standards $ - $ 1,498,000 Loss from change in fair value of interest rate swap derivatives $ - $ (1,000 ) Common stock issued upon conversion of convertible note $ - $ 500,000 Equity issued to purchase intangible assets $ - $ 145,000 Satisfaction of accrued expenses with issuance of common stock $ 114,000 $ -

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Schedule of Operations by Reportable Segment	Approximate information concerning the Company’s operations by reportable segment for the three-month ended March 31, 2020 and 2019 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Period Ended March 31, 2020 Packaging and Printing Plastics Digital Technology Management Direct Marketing Corporate Total Revenue $ 3,158,000 $ 780,000 $ 490,000 $ - $ 573,000 $ - $ 5,001,000 Depreciation and amortization 223,000 57,000 9,000 14,000 - 57,000 360,000 Interest expense 27,000 8,000 4,000 - - - 39,000 Stock based compensation 4,000 - 20,000 - - 66,000 90,000 Impairment of goodwill - (685,000 ) - - - - (685,000 ) Net Income (loss) 22,000 (1,046,000 ) (46,000 ) (241,000 ) 204,000 (860,000 ) (1,967,000 ) Capital expenditures 63,000 37,000 4,000 - - 1,000 105,000 Identifiable assets $ 10,626,000 $ 2,962,000 $ 757,000 $ - $ 865,000 $ 7,093,000 $ 22,303,000 Period Ended March 31, 2019 Packaging and Printing Plastics Digital Technology Management Direct Marketing Corporate Total Revenue $ 3,313,000 $ 1,053,000 $ 443,000 $ - $ - $ - $ 4,809,000 Depreciation and amortization 225,000 41,000 28,000 - - - 294,000 Interest expense 22,000 6,000 2,000 - - - 30,000 Stock based compensation 4,000 - 23,000 - - 4,000 31,000 Impairment of goodwill - - - - - - - Net Income (loss) 89,000 (17,000 ) (321,000 ) (56,000 ) - (146,000 ) (451,000 ) Capital expenditures 126,000 77,000 8,000 - - - 211,000 Identifiable assets $ 9,248,000 $ 4,506,000 $ 1,124,000 $ 110,000 $ - $ 1,182,000 $ 16,170,000 The following tables disaggregate our business segment revenues by major source. Printed Products Revenue Information: Three months ended March 31, 2020 Packaging Printing and Fabrication $ 2,966,000 Commercial and Security Printing 203,000 Technology Integrated Plastic Cards and Badges 220,000 Plastic Cards, Badges and Accessories 560,000 Total Printed Products $ 3,949,000 Three months ended March 31, 2019 Packaging Printing and Fabrication $ 2,961,000 Commercial and Security Printing 352,000 Technology Integrated Plastic Cards and Badges 503,000 Plastic Cards, Badges and Accessories 550,000 Total Printed Products $ 4,366,000 Technology Sales, Services and Licensing Revenue Information: Three months ended March 31, 2020 Information Technology Sales and Services $ 11,000 Digital Authentication Products and Services 331,000 Royalties from Licensees 137,000 Total Printed Products $ 479,000 Three months ended March 31, 2019 Information Technology Sales and Services $ 74,000 Digital Authentication Products and Services 230,000 Royalties from Licensees 139,000 Total Printed Products $ 443,000 Direct Marketing Three months ended March 31, 2020 Direct Marketing Internet Sales $ 573,000 Total Direct Marketing $ 573,000 Three months ended March 31, 2019 Direct Marketing Internet Sales $ - Total Direct Marketing $ -

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	Feb. 25, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 03, 2020	Dec. 31, 2019
Significant Accounting Policies [Line Items]
Impairment of goodwill		$ 685,000
Cash		3,802,000			$ 1,096,000
Working capital		$ 5,500,000
Issuance of public offering shares of common stock
Underwriting Agreement Member] | Aegis Capital Corp [Member]
Significant Accounting Policies [Line Items]
Issuance of public offering shares of common stock	25,555,556
Common stock shares exercised	851,852
Underwriting Agreement Member] | Aegis Capital Corp [Member] | Over-Allotment [Member]
Significant Accounting Policies [Line Items]
Issuance of public offering shares of common stock	3,333,333
Proceeds from net offering	$ 4,000,000
Common stock shares exercised	111,111
Customer One [Member] | Sales Revenue, Goods, Net [Member]
Significant Accounting Policies [Line Items]
Concentration of credit risk, percentage		25.00%
Customer One [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration of credit risk, percentage		54.00%
Customer Two [Member] | Sales Revenue, Goods, Net [Member]
Significant Accounting Policies [Line Items]
Concentration of credit risk, percentage		12.00%
Customer Two [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration of credit risk, percentage		5.00%
AMRE Asset Management Inc. [Member]
Significant Accounting Policies [Line Items]
Equity ownership percentage				52.50%
American Medical Reit Inc. [Member]
Significant Accounting Policies [Line Items]
Equity ownership percentage				93.00%

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Reserve for doubtful accounts	$ 2,000	$ 41,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)	Oct. 10, 2019	Nov. 11, 2019	Mar. 31, 2020	Dec. 31, 2019	Apr. 08, 2020
Outstanding principal and interest			$ 514,300	$ 507,000
Debt principal amount			802,000
Note #1 [Member]
Debt principal amount			200,000	200,000
Secured Convertible Notes [Member]
Convertible debt		$ 200,000
Debt instrument interest rate percentage		6.00%
Debt maturity date		Nov. 11, 2019
Newly issued common stock shares percentage		75.00%
Century TBD Holdings, LLC [Member]
Convertible debt	$ 500,000
Debt conversion percentage	19.80%
Debt instrument interest rate percentage	6.00%
Debt maturity date	Oct. 9, 2021
RBC Life Sciences, Inc [Member] | Second Note [Member]
Convertible debt			$ 800,000
Debt instrument interest rate percentage			10.00%
Debt maturity date			Nov. 11, 2024
Outstanding principal and interest			$ 533,000	$ 83,000
Newly issued common stock shares percentage			100.00%
RBC Life Sciences, Inc [Member] | Second Note [Member] | Subsequent Event [Member]
Ownership percentage					100.00%

Business Combination (Details N

Business Combination (Details Narrative) - USD ($)	Mar. 03, 2020	Mar. 31, 2020	Dec. 31, 2019
Common stock, par value		$ .02	$ .02
Debt principal amount		$ 802,000
Non-controlling interest		$ (67,000)
Public Offering [Member]
Initial public offering percentage		50.00%
Public Offering [Member] | Maximum [Member]
Share price		$ 10
AMRE Asset Management Inc. [Member]
Equity ownership percentage	52.50%
Incurred cost		$ 139,000
Non-controlling interest		$ 67,000
American Medical Reit Inc. [Member]
Equity ownership percentage	93.00%
Singapore eDevelopment Limited [Member]
Equity ownership percentage	82.00%
Term Sheet [Member] | LiquidValue Asset Management Pte Ltd [Member]
Equity ownership percentage	35.00%
Term Sheet [Member] | AMRE Tennessee, LLC [Member]
Equity ownership percentage	12.50%
Term Sheet [Member] | American Medical Reit Inc. [Member]
Debt instrument interest rate percentage	8.00%
Debt maturity date	Mar. 3, 2022
Debt principal amount	$ 800,000
Number of warrant to purchase shares of common stock	160,000
Warrant exercise price per share	$ 5
Warrant expiration date	Mar. 3, 2024
Term Sheet [Member] | AMRE Asset Management Inc. [Member]
Number of ordinary shares subscribed	5,250
Common stock, par value	$ 0.01
Value of ordinary shares subscribed	$ 53
Equity ownership percentage	52.50%
Term Sheet [Member] | AMRE Asset Management Inc. [Member] | LiquidValue Asset Management Pte Ltd [Member]
Number of common stock shares issues	2,500
Term Sheet [Member] | AMRE Asset Management Inc. [Member] | AMRE Tennessee, LLC [Member]
Number of common stock shares issues	1,250

Investment (Details Narrative)

Investment (Details Narrative) - Singapore eDevelopment Limited [Member] - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Number of shares owned	83,174,129
Warrant term	3 years
Warrant to purchase of common shares	44,005,182
Warrant exercise price per share	$ 0.0298
Investment		$ 2,154,000
Singapore, Dollars [Member]
Warrant exercise price per share	$ 0.040

Short-Term and Long-Term Debt (

Short-Term and Long-Term Debt (Details Narrative) - USD ($)	Mar. 02, 2020	Jun. 27, 2019	Oct. 24, 2018	Dec. 01, 2017	Apr. 28, 2015	Mar. 31, 2020	Dec. 31, 2019	Jul. 26, 2017
Debt Instrument [Line Items]
Monthly payments						$ 514,300	$ 507,000
Debt instrument, face amount						802,000
Non Revolving Line of Credit Agreement [Member] | Citizens [Member]
Debt Instrument [Line Items]
Line of credit, maximum borrowing amount						870,000
Monthly payments						13,000
Citizens Bank [Member]
Debt Instrument [Line Items]
Line of credit, maximum borrowing amount						$ 800,000
Interest rate additional rate above LIBOR						3.40%
Debt instrument, maturity date						May 31, 2020
Credit facility, amount outstanding						$ 800,000
Citizens Bank [Member] | Two Promissory Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount						$ 1,129,000
Citizens Bank [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Interest rate additional rate above LIBOR						2.00%
Premier Packaging Corporation [Member] | Citizens [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date					Apr. 28, 2020
Debt instrument, carrying amount					$ 525,000
Debt instrument, term					60 months
Interest rate on outstanding term loan					3.62%
Credit facility agreement, monthly principal payment					$ 10,000
Premier Packaging Corporation [Member] | Citizens Bank [Member] | Two Promissory Notes [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Jun. 27, 2029
Debt interest rate		4.22%
Monthly payments		$ 7,000
Debt instrument, face amount		1,200,000
Debt instrument, final balloon payment		$ 708,000
Premier Packaging Corporation [Member] | Non Revolving Line of Credit Agreement [Member] | Citizens [Member]
Debt Instrument [Line Items]
Line of credit, maximum borrowing amount								$ 1,200,000
Debt interest rate								2.00%
Plastic Printing Professionals [Member] | Two Term Notes [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date				Nov. 30, 2023
Debt interest rate				5.37%
Monthly payments				$ 14,000
Debt instrument, face amount				$ 544,000
Citizens [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, carrying amount						$ 10,000
Guangzhou Hotapps Technology Ltd [Member] | Unsecured Promissory Note [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date			Oct. 24, 2020
Unsecured promissory note			$ 100,000
American Medical Reit Inc. [Member] | Unsecured Promissory Note [Member]
Debt Instrument [Line Items]
Debt interest rate	8.00%
Debt instrument, face amount	$ 200,000
Warrant exercise price	$ 5
LiquidValue Development Pte Ltd [Member] | Unsecured Promissory Note [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Feb. 2, 2022
Warrant exercisable term	4 years

Lease Liability (Details Narrat

Lease Liability (Details Narrative)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lease description	The remaining lease terms on our operating leases range from less than one year to approximately four years.

Lease Liability - Schedule of F

Lease Liability - Schedule of Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 295,000
2021	305,000
2022	290,000
2023	270,000
2024	22,000
Total lease payments	1,182,000
Less: imputed interest	(63,000)
Lease liability	1,119,000
Current	369,000	$ 397,000
Non-current	$ 750,000	$ 826,000
Weighted-average remaining lease term (years)	3 years 4 months 28 days
Weighted-average discount rate	5.37%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Jeffrey Ronaldi [Member] - 2017 Employment Agreement [Member]	1 Months Ended
	Apr. 30, 2019USD ($)
Due to related parties	$ 100,000
Unreimbursed expenses	$ 91,000
Performance bonus percentage	15.00%

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Feb. 20, 2020	Feb. 18, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Number of common stock shares issues
Common stock, par value			$ .02		$ .02
Stock compensation expense			$ 90,000	$ 31,000
Basic and diluted earnings per share			$ 0.06	$ 0.06
Common Stock [Member]
Number of common stock shares issues			863,000	19,000
Underwriting Agreement Member] | Common Stock [Member]
Number of common stock shares issues	22,222,223
Underwriting Agreement Member] | Additional Shares [Member]
Number of common stock shares issues	3,333,333
Underwriter Member] | Underwriting Agreement Member]
Proceeds from net offering	$ 4,000,000
Underwriter Member] | Underwriting Agreement Member] | Common Stock [Member]
Number of common stock shares issues	740,741
Common stock, par value	$ 0.02
Share issued price per shares	5.40
Pre-reverse stock split per share	$ 0.18
Underwriter Member] | Underwriting Agreement Member] | Additional Shares [Member]
Number of common stock shares issues	111,111
Mr. Heng Fai Ambrose Chan [Member]
Accrued salary			$ 61,000		$ 114,000
Mr. Heng Fai Ambrose Chan [Member] | Underwriting Agreement Member]
Proceeds from net offering	$ 2,000,000
Common stock were remitted in lieu of cash		11,664

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Supplemental Cash Flow Information [Abstract]
Cash paid for interest	$ 39,000	$ 30,000
Impact of adoption of lease accounting standards		1,498,000
Loss from change in fair value of interest rate swap derivatives		(1,000)
Common stock issued upon conversion of convertible note		500,000
Equity issued to purchase intangible assets		145,000
Satisfaction of accrued expenses with issuance of common stock	$ 114,000

Segment Information (Details Na

Segment Information (Details Narrative)	3 Months Ended
	Mar. 31, 2020Integer
Segment Reporting [Abstract]
Number of operating segment	5

Segment Information - Schedule

Segment Information - Schedule of Operations by Reportable Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 5,001,000	$ 4,809,000
Depreciation and amortization	360,000	294,000
Stock based compensation	90,000	31,000
Impairment of goodwill	(685,000)
Net Income (loss)	(1,967,000)	(451,000)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	5,001,000	4,809,000
Depreciation and amortization	360,000	294,000
Interest expense	39,000	30,000
Stock based compensation	90,000	31,000
Impairment of goodwill	(685,000)
Net Income (loss)	(1,967,000)	(451,000)
Capital expenditures	105,000	211,000
Identifiable assets	22,303,000	16,170,000
Operating Segments [Member] | Packaging and Printing [Member]
Segment Reporting Information [Line Items]
Revenue	3,158,000	3,313,000
Depreciation and amortization	223,000	225,000
Interest expense	27,000	22,000
Stock based compensation	4,000	4,000
Net Income (loss)	22,000	89,000
Capital expenditures	63,000	126,000
Identifiable assets	10,626,000	9,248,000
Operating Segments [Member] | Plastics [Member]
Segment Reporting Information [Line Items]
Revenue	780,000	1,053,000
Depreciation and amortization	57,000	41,000
Interest expense	8,000	6,000
Stock based compensation
Impairment of goodwill	(685,000)
Net Income (loss)	(1,046,000)	(17,000)
Capital expenditures	37,000	77,000
Identifiable assets	2,962,000	4,506,000
Operating Segments [Member] | Digital [Member]
Segment Reporting Information [Line Items]
Revenue	490,000	443,000
Depreciation and amortization	9,000	28,000
Interest expense	4,000	2,000
Stock based compensation	20,000	23,000
Net Income (loss)	(46,000)	(321,000)
Capital expenditures	4,000	8,000
Identifiable assets	757,000	1,124,000
Operating Segments [Member] | Technology Management [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	14,000
Interest expense
Stock based compensation
Net Income (loss)	(241,000)	(56,000)
Capital expenditures
Identifiable assets		110,000
Operating Segments [Member] | Direct Marketing [Member]
Segment Reporting Information [Line Items]
Revenue	573,000
Depreciation and amortization
Interest expense
Stock based compensation
Net Income (loss)	204,000
Capital expenditures
Identifiable assets	865,000
Operating Segments [Member] | Corporate [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	57,000
Interest expense
Stock based compensation	66,000	4,000
Net Income (loss)	(860,000)	(146,000)
Capital expenditures	1,000
Identifiable assets	$ 7,093,000	$ 1,182,000

Segment Information - Schedul_2

Segment Information - Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Total Printed Products	$ 3,949,000	$ 4,366,000
Total Technology Sales, Services and Licensing	479,000	443,000
Direct Marketing	573,000
Packaging Printing and Fabrication [Member]
Segment Reporting Information [Line Items]
Total Printed Products	2,966,000	2,961,000
Commercial and Security Printing [Member]
Segment Reporting Information [Line Items]
Total Printed Products	203,000	352,000
Technology Integrated Plastic Cards and Badges [Member]
Segment Reporting Information [Line Items]
Total Printed Products	220,000	503,000
Plastic Cards, Badges and Accessories [Member]
Segment Reporting Information [Line Items]
Total Printed Products	560,000	550,000
Information Technology Sales and Services [Member]
Segment Reporting Information [Line Items]
Total Technology Sales, Services and Licensing	11,000	74,000
Digital Authentication Products and Services [Member]
Segment Reporting Information [Line Items]
Total Technology Sales, Services and Licensing	331,000	230,000
Royalties from Licensees [Member]
Segment Reporting Information [Line Items]
Total Technology Sales, Services and Licensing	137,000	139,000
Direct Marketing Internet Sales [Member]
Segment Reporting Information [Line Items]
Direct Marketing	$ 573,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 07, 2020	Apr. 27, 2020	Apr. 03, 2020	Mar. 31, 2020	Mar. 31, 2019
Number of common stock shares issues
Value of common stock shares issues				$ 4,054,000	$ 638,000
Common Stock [Member]
Number of common stock shares issues				863,000	19,000
Value of common stock shares issues				$ 18,000
Subsequent Event [Member]
Reverse stock split	1-for-30 reverse stock split
Subsequent Event [Member] | Share Exchange Agreement [Member] | DSS Technology Management [Member]
Number of common stock shares issues		50,000,000
Subsequent Event [Member] | Share Exchange Agreement [Member] | DSS Technology Management [Member] | Convertible Preferred Stock [Member]
Number of common stock shares issues		46,868
Value of common stock shares issues		$ 46,868,000
Shares issued price per share		$ 1,000
Beneficial ownership percentage		19.90%
Liquidation of preferred stock per share		$ 1,000
Subsequent Event [Member] | Share Exchange Agreement [Member] | DSS Technology Management [Member] | Common Stock [Member]
Number of common stock shares issues		14,500,000
Value of common stock shares issues		$ 3,132,000
Shares issued price per share		$ 0.216
Subsequent Event [Member] | Equity Incentive Plan [Member]
Number of common stock shares issues			8,900
Shares issued price per share			$ 0.22
Number of shares vested			5,800